Şunu aradınız:: were administered (İngilizce - Maltaca)

cycles were administered at 3 week intervals.
iċ-ċikli ngħataw f’intervalli ta’ 3 ġimgħat.

both regimens were administered every 3 weeks.
il-pazjenti fiż-żewġ gruppi ngħataw il-mediċini kull 3 ġimghat.

olaratumab and doxorubicin were administered by intravenous infusion.
olaratumab u doxorubicin ingħataw permezz ta’ infużjoni fil-vini.

doxorubicin and cyclophosphamide were administered concurrently as follows:
doxorubicin u cyclophosphamide ingħataw flimkien kif ġej:

isentress and efavirenz were administered with emtricitabine (+) tenofovir.
isentress u efavirenz ingħataw ma’ emtricitabine (+) tenofovir.

both regimens were administered on day 1 every 3 weeks.
iż- żewġ sistemi ta’ trattament ingħataw fl-ewwel jum ta’ kull 3 ġimgħat.

all treatment cycles were administered at intervals of 3 weeks.
iċ-ċikli kollha ta’ kura ingħataw f’intervalli ta’ 3 ġimgħat.

both regimens were administered once every 3 weeks for 6 cycles.
iż-żewġ gruppi kienu ngħataw il-kura darba kull 3 ġimgħat għal 6 ċikli.

one or 2 laser light treatments were administered following photobarr injection.
wara l-injezzjoni ta’ photobarr, il-pazjenti ngħataw trattament jew tnejn bid-dawl laser.

over 94,000 doses of dukoral were administered during the clinical trials.
l- evalwazzjoni tas- sigurtà kienet differenti bejn prova u oħra minħabba varjazzjonijiet fil- mod ta ’ sorveljanza, ta ’ definizzjoni tas- sintomi, u t- tul taż- żmien ta ’ visti sussegwenti.

growth factors were administered to 19 % of patients in 8 % of courses.
19 % tal-pazjenti ngħataw growth factors f’8 % tal-korsijiet.

no interaction was observed when cholestagel and pioglitazone were administered simultaneously in healthy volunteers
ma kienet osservata l-ebda interazzjoni meta cholestagel u pioglitazone ingħataw fl-istess ħin f’voluntiera b’saħħithom.

in a clinical study, 100 infants with hiv infection were administered rotarix or placebo.
fi studju kliniku, rotarix jew plaċebo ngħata lil 100 tarbija bl-infezzjoni ta’ l-hiv.

adjuvant corticosteroids, including dexamethasone, were administered with chemotherapy in 55% of patients.
kortikosterojdi adjuvanti, li jinkludu dexamethasone, ingħataw ma’ kimoterapija f’55% tal-pazjenti.

doses of naloxegol up to 1,000 mg were administered in healthy volunteers in clinical studies.
ingħataw dożi ta’ naloxegol sa 1,000 mg f’voluntiera b’saħħithom fi studji kliniċi.

in these studies, rabbits were administered 3, 10 and 20 mg/kg/day orally.
f’dawn l-istudji, il-fniek ngħataw 3, 10 u 20 mg/kg/kuljum oralment.

in an early uncontrolled study without dexamethasone prophylaxis, single doses up to 125 mg were administered.
fi studju bikri mhux ikkontrollat mingħajr profilassi ta’ dexamethasone, dożi waħidhom sa 125 mg kienu mogħtija.

patients were administered intravenous doses of 0.7 to 1.3 mg/m2 of velcade twice weekly.
il-pazjenti ngħataw dożi minn 0.7 sa 1.3 mg/m2 ta’ velcade ġol-vina darbtejn fil-ġimgħa.

oxaliplatin-based regimens were administered in combination with bevacizumab in 373 patients (30.4%).
korsijiet ibbażati fuq oxaliplatin ingħataw flimkien ma’ bevacizumab lill-373 pazjent (30.4%).

less often substances such as propranolol and benzodiazepines (clonazepam and diazepam) were administered to control akathisia.
inqas ta’ spiss sustanzi bħal propranolol u benzodiazepines (clonazepam u diazepam) ġew amministrati biex jikkontrollaw akatisja.